Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 53-64

  Ioakeimidis, Nikolaos ^a   Kostis, John B ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

cardiovascular disease; erectile dysfunction; PDE5 inhibitors

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HEARING IMPAIRMENT; HEART FAILURE; HUMAN; ISCHEMIC OPTIC NEUROPATHY; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VISUAL DISORDER;

CARDIOVASCULAR DISEASE; ERECTILE DYSFUNCTION; PDE5 INHIBITORS;

ANIMALS; CARBOLINES; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ERECTILE DYSFUNCTION; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PURINES; SULFONES;

EID: 84890958667     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413504034     Document Type: Review

References (82)

1. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 year old: longitudinal results from the Massachusetts male aging study. J Urol. 2000 ; 163 (2). 460-463
2. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013 ; 381 (9861). 153-165
3. Ryan JG, Gajraj J. Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus. J Diabetes Complications. 2012 ; 26 (2). 141-147
4. Gandaglia G, Salonia A, Passoni N, Montorsi P, Briganti A, Montorsi F. Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. Endocrine. 2013 ; 43 (2). 285-292
5. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract. 2010 ; 64 (7). 848-857
6. Jackson G. Erectile dysfunction and coronary disease: evaluating the link. Maturitas. 2012 ; 72 (3). 263-264
7. Meldrum DR, Gambone JC, Morris MA, Meldrum DA, Esposito K, Ignarro LJ. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol. 2011 ; 108 (4). 599-606
8. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 ; 49 (6). 822-830
9. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol. 2006 ; 50 (4). 721-731
10. Araujo AB, Hall SA, Ganz P, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score?. J Am Coll Cardiol. 2010 ; 55 (4). 350-356
11. Bohm M, Baumhakel M, Teo K, et al. ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Circulation. 2010 ; 121 (12). 1439-1446
12. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phos-phodiesterase inhibitors. J Am Coll Cardiol. 2008 ; 51 (21). 2040-2044
13. Miner M, Seftel AD, Nehra A, et al. Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J. 2012 ; 164 (1). 21-28
14. Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all cause mortality with erectile dysfunction. a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013 ; 6 (1). 99-109
15. Sáenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2002 ; 14 (suppl 1). S6 - S10
16. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Stefanadis C. The triad: erectile dysfunction-endothelial dysfunction-cardiovascular disease. Curr Pharm Des. 2008 ; 14 (35). 3700-3714
17. Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010 ; 7 (1 Pt 2). 445-475
18. Persu C, Cauni V, Gutue S, Albu ES, Jinga V, Geavlete P. Diagnosis and treatment of erectile dysfunction - a practical update. J Med Life. 2009 ; 2 (4). 394-400
19. El-Sakka AI. Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two?. J Sex Med. 2011 ; 8 (4). 937-940
20. Rajfer J, Rosciszewski A, Mehringer M. Prevalence of corporeal venous leakage in impotent men. J Urol. 1988 ; 19 (1). 69-71
21. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J. 2006 ; 27 (22). 2640-2648
22. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994 ; 34 (10). 989-996
23. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013 ; 10 (1). 245-284
24. Lin CS, Lin G, Xin ZC, Lue TF. Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des. 2006 ; 12 (27). 3439-357
25. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des. 2006 ; 12 (27). 3485-3494
26. Zaccolo M. Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007 ; 100 (11). 1569-1578
27. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003 ; 92 (9A). 9M - 18M
28. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000 ; 84 (2). E4
29. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007 ; 19 (3). 253-264
30. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des. 2009 ; 15 (30). 3464-3475
31. Baumhäkel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Böhm M. Cardiovascular risk, drugs and erectile function - a systematic analysis. Int J Clin Pract. 2011 ; 65 (3). 289-298
32. Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep. 2012 ; 14 (4). 285-292
33. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010 ; 7 (1 Pt 2). 524-540
34. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010 ; 64 (2). 240-255
35. Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2002 ; 162 (12). 1349-1360
36. Berookhim BM, Bar-Chama N. Medical implications of erectile dysfunction. Med Clin North Am. 2011 ; 95 (1). 213-221
37. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med. 2011 ; 8 (12). 3418-3432
38. Scranton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med. 2013 ; 10 (2). 551-561
39. Matic H, McCabe MP. Duration of erectile dysfunction and its relationship to treatment seeking and satisfaction with treatment using PDE5 inhibitors. Int J Urol. 2008 ; 15 (4). 346-349
40. Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011 ; 8 (10). 2894-2903
41. Olsson AM, Persson C-A. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Prac. 2001 ; 55 (3). 171-176
42. DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004 ; 93 (2). 147-153
43. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med. 2009 ; 6 (3). 658-674
44. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012 ; 59 (1). 9-15
45. Apostolo A, Vignati C, Brusoni D, et al. Erectile dysfunction in heart failure: correlation with severity, exercise performance, comorbidities, and heart failure treatment. J Sex Med. 2009 ; 6 (10). 2795-2805
46. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007 ; 116 (14). 1555-1562
47. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011 ; 4 (1). 8-17
48. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007 ; 50 (22). 2136-2144
49. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 ; 309 (12). 1268-1277
50. Frantzen J, Speel TG, Kiemeney LA, Meuleman EJ. Cardiovascular risk among men seeking help for erectile dysfunction. Ann Epidemiol. 2006 ; 16 (2). 85-90
51. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest. 2005 ; 128 (4). 3065-3067
52. Mancia G, Laurent S, Agabiti-Rosei E, et al. European society of hypertension. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens. 2009 ; 27 (11). 2121-2158
53. Chrysant SG, Chrysant GS. The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J Clin Hypertens. 2012 ; 14 (9). 644-649
54. Attinà TM, Drummond ID, Malatino LS, Maxwell SR, Webb DJ. Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. Am J Hypertens. 2013 ; 26 (3). 342-350
55. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006 ; 151 (4). 851.e1 - e5
56. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007 ; 120 (3). 301-305
57. O'Donnell JM. William harvey research conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Expert Opin Investig Drugs. 2000 ; 9 (3). 621-625
58. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011 ; 72 (4). 634-646
59. Dunkern TR, Hatzelmann A. The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal. 2005 ; 17 (3). 331-339
60. Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, Sessa WC, Papapetropoulos A. The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol. 1007 ; 211 (1). 197-204
61. Zhu B, Zhang L, Alexeyev M, Alvarez DF, Strada SJ, Stevens T. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am J Physiol Lung Cell Mol Physiol. 2009 ; 296 (2). L220 - L228
62. Nehra A, Jackson G, Miner M, et al. The princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 ; 87 (8). 766-778
63. Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. Eur Heart J. 2013 ; 34 (27). 2034-2046
64. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA. 2002 ; 287 (6). 719-725
65. Thadani U, Smith W, Nash S, et al. The effects of vardenafil, a potent and highly selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2002 ; 40 (11). 2006-2012
66. Patterson D, MacDonald TM, Effron MB. Tadalafil does not affect time to ischemia during exercise testing in patients with coronary artery disease. Circulation. 2002 ; 106 (suppl II). II - 330
67. Fox KM, Thadani U, Ma PT, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J. 2003 ; 24 (24). 2206-2212
68. Baraghoush A, Phan A, Willix RD, Schwarz ER. Erectile dysfunction as a complication of heart failure. Curr Heart Fail Rep. 2010 ; 7 (4). 194-201
69. Giagulli VA, Moghetti P, Kaufman JM, Guastamacchia E, Iacoviello M, Tirggiani V. Managing erectile dysfunction in heart failure. Endocr Metab Immune Disord Drug Targets. 2013 ; 13 (1). 125-134
70. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353 (20). 2148-2157
71. Galiè N, Brundage BH, Ghofrani HA, et al. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 ; 119 (22). 2894-2903
72. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004 ; 44 (7). 1488-1496
73. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007 ; 116 (3). 238-248
74. Sun YJ, Yang T, Zeng WJ, et al. Impact of sildenafil on survival of patients with eisenmenger syndrome. J Clin Pharmacol. 2013 ; 53 (6). 611-618
75. Mukhopadhyay S, Sharma M, Ramakrishnan S. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006 ; 24;114 (17). 1807-1810
76. Lim ZS, Salmon AP, Vettukattil JJ, Veldtman GR. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol. 2007 ; 118 (2). 178-182
77. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second princeton consensus conference). Am J Cardiol. 2005 ; 96 (2). 313-321
78. Jackson G. Sexual response in cardiovascular disease. J Sex Res. 2009 ; 46 (2-3). 233-236
79. Rosen RC, Friedman M, Kostis JB. Lifestyle management of erectile dysfunction: the role of cardiovascular and concomitant risk factors. Am J Cardiol. 2005 ; 96: 12B 76M - 79M
80. Meldrum DR, Gambone JC, Morris MA, Esposito K, Giugliano D, Ignarro LJ. Lifestyle and metabolic approaches to maximizing erectile and vascular health. Int J Impot Res. 2012 ; 24 (2). 61-68
81. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011 ; 171 (20). 1797-1803
82. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010 ; 95 (6). 2536-2559